Send Message
View as an RSS Feed
  • The Bottom Is In. Now What? - Bezek's Daily Briefing  [View article]
    Yep, and sure looks like a fading rally again today.
    Jan 21, 2016. 02:20 PM | Likes Like |Link to Comment
  • No, Virginia; Biotech Is Not In A Bubble  [View article]
    Well, I don't know if you would consider RLYP farthest out on the risk curve, or being unfairly punished, but it seems that one would be well worth picking up some shares because of the likelihood of a buyout soon (within a year possibly.) To me that takes some of the risk out. Sellers are clearly making the shorts rich at the moment, but I plan to add if the selling abates. I would like to see an uptick first, since I don't like buying falling knives.

    Bret, I would like to know if you look at it that way, or have another opinion.
    Jan 12, 2016. 03:24 PM | 1 Like Like |Link to Comment
  • Tough run continues for New York Mortgage after dividend cut  [View news story]
    Answers in brief and in order:
    Share price has nothing to do with dividend sustainability.
    NYMT shares were formerly priced at a premium because investors considered it more reliable/stable in this environment. That changed when the CEO insinuated the dividend was sustainable in the last conference call, but then cut it shortly thereafter. Now investors are cutting the premium as the risk is perceived as substantially higher than formerly thought.
    Sep 29, 2015. 03:23 PM | 2 Likes Like |Link to Comment
  • What To Make Of The Chaos At Acadia  [View article]
    Nonsense. There isn't now and has not been a one-sided trade in this stock. There has been a substantial short position for quite some time and their main premise was that the NDA filing would be delayed. I'm long ACAD and knew that, but thought it unlikely based on what I knew. The shorts turned out to be right this time. I always try to have an eye on the risks, but determined if the company had trouble transitioning to commercializing, it would be disappointing but not fatal as long as the drug story is still intact. It is.

    The interim CEO admitted on the CC that mistakes were made and they didn't start certain processes soon enough. They owned up and I give them the benefit of the doubt at this point, since they executed the clinical process brilliantly, and drugs with Nuplazid's potential don't come along very often. Any further big muff-ups and no doubt it won't be pretty, but as long as the Nuplazid status is intact I think your downside target is unlikely.
    Mar 16, 2015. 03:44 PM | 3 Likes Like |Link to Comment
  • Acadia Pharmaceuticals: Strong Balance Sheet And Several Near-Term Catalysts  [View article]
    They cancelled a March 3rd conference also, not just today's. The thought of ACAD getting bought out at anything close to today's closing price is enough to make me ill. Why in the world would management want to do that?
    Mar 10, 2015. 06:21 PM | Likes Like |Link to Comment
  • An ETF Portfolio Yielding 9%  [View article]
    I have misgivings about this ETF portfolio. The individual ETFs may not be highly correlated with each other, but almost all are either greatly affected by the price of oil and fear of defaults by struggling energy companies and/or are highly sensitive to rising interest rates. On the 3-yr. chart the portfolio did well right up until oil started tanking in earnest and the Fed started making more noise about raising rates. The chart tops out in September of last year and lurched into a downtrend that I suspect will only continue, and I don't think the high yield makes up for the potential losses ahead for this bunch of ETFs. The scenario changed in 2014 for many of them. Instead of this being a high-yield portfolio with lower risk as the author intended, I think it is high risk. Just my opinion. It would be interesting to see if this chart is as pretty at the end of 2015 as it was at the end of 2013.
    Jan 11, 2015. 04:07 PM | Likes Like |Link to Comment
  • A Diversified, High-Income, Lower-Risk CEF Portfolio For 2015  [View article]
    Schwab also gives the online option of reinvesting dividend payers at no cost. But I am surprised to see you included Scottrade in brokerages who do. I keep only individual stocks there because as of last spring they had no automatic dividend reinvestment. Because of that, I rolled over a 401k that I want dedicated to dividend producers to another brokerage.
    Jan 1, 2015. 08:15 PM | 2 Likes Like |Link to Comment
  • XOMA sell-off continues  [View news story]
    XOMA has been the subject of an aggressive pump by newsletters recently tagging it as a millionaire maker on news expected any day now. I presume they banked on results being divulged at the presentation, which didn't happen, and it has just gone down as much as it went up on the pump the last few weeks. This kind of thing is par for the course with tiny companies like XOMA.
    Dec 5, 2014. 03:18 PM | 1 Like Like |Link to Comment
  • Report: Amazon Prime to $99  [View news story]
    Okay. But unless you pay zero interest rates on the card, it's not free.
    Mar 13, 2014. 04:54 PM | Likes Like |Link to Comment
  • Cytokinetics +32% after Q4 earnings beat estimates, revenue soars  [View news story]
    Long but still in total shock. In no way, shape, or form did I see anything like this coming. Wow.
    Feb 7, 2014. 01:56 PM | Likes Like |Link to Comment
  • Oxford Lane Capital's New Rights Offering: Not The No-Brainer Of A Year Ago  [View article]
    I will wait till Feb 5th to see what the company gives as the NAV before I decide, but quite frankly, if the exercise price isn't a good bit below NAV I see little incentive to participate. Unless management guided expectations for substantially increasing earnings in the near future (and no, I don't think that's likely) there's nothing advantageous about this rights offering. There may be some that would add for the increased and special dividend since they could excercise in time to qualify.
    Jan 29, 2014. 06:46 PM | Likes Like |Link to Comment
  • 5 High-Yield Monthly Income Investments For 2014  [View article]
    I own CEFL. It held up well in last week's downdraft in my opinion, down only 1.5% while the DOW was down 5%.
    Jan 26, 2014. 02:08 AM | Likes Like |Link to Comment
  • Tonix prices secondary at $15 each  [View news story]
    It's smart of them to both fund the PTSD trials and increase the float enough to support institutional buyers. They needed to make more shares available for that purpose, and I agree with Garrett- better now than later. $15 is the new floor for the stock, and if the trials are successful, the dilution will hardly matter.
    Jan 24, 2014. 07:53 PM | 1 Like Like |Link to Comment
  • Is There Still Room To Profit With Halozyme?  [View article]
    Today's news: CHMP recommended MabThera for approval. Biggest risk is out of it now. Good chance to add with the selloff. The stock should start reflecting the news once things settle down.
    Jan 24, 2014. 01:46 PM | Likes Like |Link to Comment
  • A Glimpse At Our Small Cap Biotechnology Portfolio  [View article]
    Long CTSO and have waited a very long time for the company to step on the accelerator, but it finally seems to be happening. They have distribution agreements in place now in many parts of the world and the distributors will do much of the marketing for them. I like investing in good products that answer unmet needs, and for sepsis in ICUs and cardiac surgery applications, they are ahead of everyone else, besides the other things mentioned in the article. I am looking forward to seeing what progress they make this year. Too many people die of sepsis; CTSO's products save lives- the U.S. trial news should come soon.

    Nice to see this company included in your article. Thank you for the interesting picks to explore.
    Jan 21, 2014. 03:22 PM | 1 Like Like |Link to Comment